| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TENX | Common Stock | Award | +512K | +540.97% | 607K | 11 Jun 2021 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TENX | Stock Option (right to buy) | Award | $0 | +6.25K | $0.00 | 6.25K | 10 Jun 2021 | Common Stock | 6.25K | $2.00 | Direct | ||
| transaction | TENX | Series B Preferred Stock | Options Exercise | -512 | -100% | 0 | 11 Jun 2021 | Common Stock | 512K | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021. |
| F2 | As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. |